Company description:
Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies.
Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).
Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Job description:
Join Us in Changing Lives
At? OXB, our people are at the heart of everything we do.Wereon a mission to enable life-changing therapies to reach patients around the worldandwerelooking for passionate individuals who embody our core values every day:? Responsible, Responsive, Resilient, and Respectful .
Werecurrently recruiting for a Senior Procurement Specialist to join our Procurement team for a maternity cover. In this role, you will?support the on-going development of the function ensuring continuity and quality of the procurement service to the business.
Your responsibilities in this role would be:
To implement procurement policies across all areas of the business.
Share the ownership of a direct and indirect spend circa £125 Million.
Develop and maintain stakeholder and key supplier relationships, both internally and externally, globally, at all levels.
Drive innovation in procurement, streamlining the strategies, and adding value on major television projects.
Manage long term pipelines for procurement, developing plans in line with the future goals of the organisation.
Work cross functionally across OXB to ensure that the procurement process is maximizing value to the organisation and delivering best practices.
Support end to end sourcing strategies helping transition the procurement team from transactional to a more a strategic function focusing on category management & SRM development.
Build strong relationships across the business and with the supplier base, ensuring that business strategies are integrated into the procurement planning process.
Flexible hybrid working arrangement available for the right candidate.
Profile description:
We are looking for:
Education to bachelors degree level (or equivalent).
A proven history of working within procurement, with evidence of both value adding and cost reduction via implementing effective sourcing strategies.
Good Category management and Supplier performance management experience.
Proven experience with Enterprise Resource Planning (ERP) Systems
Experience within Pharma or Biotech or similar regulated environment
Excellent communicator with the ability to engaging, building relationships, collaborate and influence with senior stakeholders both internally and externally.
Ability to work both individually and as a team.
The ability to create, analyse and drive data driven decisions.
About Us:
OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than30years of experience in viral vectors; the driving force behindthe majority ofgene therapies.
OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturingexpertisein lentivirus, adeno-associated virus (AAV)and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatoryexpertise.
Why Join Us?
???Competitive total reward packages
???Wellbeing programmes?that support your mental and physical health
???Career development opportunities?to help you grow and thrive
???Supportive, inclusive, and collaborative culture
???State-of-the-art labs and manufacturing facilities
??A company that lives its values:? Responsible, Responsive, Resilient, Respect
We want you to feel inspired every day. AtOXB,werefuture-focused and growing fast. We succeed togetherthrough passion, commitment, and teamwork.
Ready to Make a Difference?
Collaborate. Contribute. Change lives.
We offer:
Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies.
Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).
Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
TPBN1_UKTJ